Dealscape | Medtech capital Raising

Recently, I attended an AdvaMed webinar focused on fundraising dynamics in the MedTech sector. A few key insights stood out for founders and operators navigating today's market ↓

𝐈𝐧𝐯𝐞𝐬𝐭𝐨𝐫 𝐀𝐥𝐢𝐠𝐧𝐦𝐞𝐧𝐭 𝐚𝐧𝐝 𝐒𝐭𝐫𝐮𝐜𝐭𝐮𝐫𝐞

‣ Target investors thoughtfully: Individual angels, angel groups, and early-stage VCs each require tailored messaging

‣ Consider expanding your outreach to include different investor types. For example, if your device leverages AI, it may be worthwhile to target AI-focused investors in addition to traditional MedTech investors.

‣ Deal structure may vary by geography. For example, SAFEs remain common in the Western US but some East Coast investors still prefer convertible notes.

𝐌𝐚𝐫𝐤𝐞𝐭 𝐃𝐲𝐧𝐚𝐦𝐢𝐜𝐬

‣ The coasts are saturated with MedTech pitches; Midwest markets may offer more genuine enthusiasm.

‣ Pure R&D-stage companies typically fall outside venture mandates and may be better suited to angels, incubators, or similar programs.

‣ Be prepared to explain your technical, regulatory, clinical, and commercial milestones clearly, and how and when you will reach them.

𝐏𝐨𝐬𝐢𝐭𝐢𝐨𝐧𝐢𝐧𝐠 𝐚𝐧𝐝 𝐃𝐢𝐬𝐜𝐢𝐩𝐥𝐢𝐧𝐞

‣ Stay focused. Do not pitch a multiplicity of initiatives at once.

‣ Pitching large funds too early can lead to overexposure without progress. On the other hand, doing so provides great experience and practice. Choose strategically.

‣ Protect truly proprietary information. Align your team on what can be disclosed.

𝐈𝐏 𝐒𝐭𝐫𝐚𝐭𝐞𝐠𝐲

‣ Investors are less interested in patent quantity and more in how your IP secures market access.

‣ Show how differentiation will translate into execution, not just novelty.

𝐅𝐢𝐧𝐚𝐥 𝐓𝐡𝐨𝐮𝐠𝐡𝐭𝐬

‣ Learning from feedback is important, but don’t compromise your core vision.

‣ Investor interest should be mutual. Your "yes" matters too.

‣ Lack of traction often speaks for itself. Where interest is light, refine the message and tighten your approach.